The Hidden Regulatory Risks Behind the GLP-1 Boom: Evidence from FDA Warning Letters

1. Executive Summary

The rapid expansion of the market for Glucagon-Like Peptide-1 (GLP-1) receptor agonists, primarily semaglutide and tirzepatide, has created unprecedented consumer demand and a corresponding surge in parallel supply channels. This report conducts a systematic, evidence-based analysis of the regulatory risks underlying this boom, drawing on a review of United States Food and Drug Administration (FDA) warning letters, statutory provisions, and regulatory guidance documents issued between 2024 and 2026. The primary objective of this research is to delineate the legal boundaries of drug compounding, identify the specific violations cited by the FDA, and evaluate the strategic implications for telehealth platforms, compounding pharmacies, and active pharmaceutical ingredient (API) suppliers.

The methodology employed involves a thematic synthesis of FDA compliance actions, focusing on warning letters issued by the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH). By analyzing warning letters issued to online clinics, traditional compounding pharmacies, API distributors, and nonclinical laboratories, this study maps the regulatory landscape and identifies critical compliance patterns.

The key findings of this analysis are fourfold. First, the FDA has executed a coordinated enforcement campaign against online clinics and telehealth platforms for misbranding and false or misleading claims. These entities frequently market compounded GLP-1 products using language that falsely implies FDA approval, generic equivalence, or identical safety and efficacy profiles to brand-name products such as Ozempic, Wegovy, Mounjaro, and Zepbound. Second, the FDA has cracked down on compounding pharmacies that produce “essentially copies” of commercially available drugs with minor formulation changes. A prominent example is the September 18, 2026 warning letter to Empower Pharmacy, which cited high-volume production of tirzepatide combined with niacinamide and semaglutide combined with cyanocobalamin. Third, the end of the FDA’s enforcement discretion periods in 2025 (for state-licensed pharmacies, March 5, 2025 for tirzepatide and April 24, 2025 for semaglutide; for outsourcing facilities, March 19 and May 22, 2025) has eliminated the earlier regulatory leeway, so compounding these drugs as “essentially copies” is prohibited unless they return to the FDA drug shortage list. Fourth, the FDA has targeted the distribution of unapproved next-generation peptides, such as retatrutide and cagrilintide, which fail to meet any statutory compounding exemption under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The principal conclusion of this report is that the FDA is actively enforcing the compounding rules across the GLP-1 market. The agency’s actions target the entire supply chain, from upstream bulk API distributors to downstream telehealth marketing platforms. Market participants must align their operations with the statutory requirements of Sections 503A and 503B, cease misleading comparative advertising, and ensure that any bulk substances used are eligible for compounding. Failure to do so carries severe legal, financial, and reputational risks, including product seizures, injunctions, and criminal prosecution.

2. Introduction

The global pharmaceutical landscape has been fundamentally reshaped by the advent of highly effective weight-loss and diabetes medications. GLP-1 receptor agonists, such as semaglutide and tirzepatide, have transitioned from specialized clinical treatments to mainstream cultural and economic phenomena. This surge in demand outstripped the manufacturing capacity of the originator companies, resulting in prolonged drug shortages.

To fill this supply-demand gap, a large parallel market emerged, made up of state-licensed compounding pharmacies, outsourcing facilities, online telehealth clinics, and bulk chemical distributors. While drug compounding plays a vital role in the healthcare system by providing customized medications for patients with unique clinical needs, its rapid commercialization during the GLP-1 boom has introduced significant regulatory, legal, and clinical risks.

Problem Statement and Research Questions

The proliferation of compounded GLP-1 formulations has led to widespread regulatory non-compliance. Many market participants operate under the mistaken assumption that drug shortages grant a blanket exemption from standard FDA approval and labeling requirements. Consequently, the market has been flooded with unapproved “new drugs,” misbranded formulations, and unauthorized next-generation peptides. This research addresses the following core questions:

1. What are the primary regulatory violations cited by the FDA against entities marketing compounded GLP-1 products?
2. How does the FDA define and enforce the “essentially a copy” restriction under Sections 503A and 503B of the FD&C Act?
3. What are the regulatory statuses and compounding eligibilities of next-generation peptides like retatrutide and cagrilintide?
4. What are the implications of the end of enforcement discretion for semaglutide and tirzepatide compounding?

Theoretical and Regulatory Framework

This analysis is grounded in the statutory framework of the FD&C Act. Specifically, it examines:

• Section 502 (Misbranding): Deeming a drug misbranded if its labeling or advertising is false or misleading in any particular.
• Section 503A (Traditional Compounding): Governing compounding by state-licensed pharmacies or physicians for individual patients.
• Section 503B (Outsourcing Facilities): Governing larger-scale compounding of sterile drugs under Current Good Manufacturing Practice (CGMP) standards.
• Section 505 (New Drug Approval): Prohibiting the introduction of unapproved “new drugs” into interstate commerce.

This report is structured to provide a systematic review of these regulatory mechanisms, followed by a data analysis of recent FDA warning letters, a discussion of industry implications, and conclusions for market stakeholders.

3. Literature Review & Analysis

The FDA’s regulatory oversight of the GLP-1 market is characterized by a multi-front enforcement strategy. This section synthesizes the key themes, statutory provisions, and compliance patterns identified across recent FDA warning letters and guidance documents.

Theme 1: Misbranding and False or Misleading Claims (Sections 502(a) and 502(bb))

Under Section 502(a) of the FD&C Act, a drug is deemed misbranded if its labeling is false or misleading in any particular. Section 502(bb) applies this standard to compounded drugs: a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.

The FDA has issued a wave of warning letters to online clinics, telehealth platforms, and compounding pharmacies for violating these sections, including a group of letters dated June 8, 2026. The primary violations stem from marketing claims that imply compounded GLP-1 products are identical to, or have the same FDA approval as, brand-name medications like Ozempic, Wegovy, Mounjaro, and Zepbound. Examples of the kinds of claims at issue include:

• Describing compounded formulations as “generic semaglutide.”
• Stating that the products are “similar to Ozempic or Wegovy.”
• Claiming the products contain the “same active ingredient” or deliver the “same results” as the branded counterparts.

Because compounded drug products do not undergo FDA pre-market review for safety, efficacy, or manufacturing quality, these comparative claims are false or misleading. Furthermore, describing compounding pharmacies or outsourcing facilities as “FDA-approved” or “FDA-licensed” is misleading, because the FDA does not approve or license any facility.

The FDA has also targeted misleading source representation, where telehealth platforms put their own names or logos on product labels, suggesting they are the compounders of the drugs when they are not. Examples include OrderlyMeds, AM RX and NOVARX, all cited on June 8, 2026. Introducing or delivering these misbranded products into interstate commerce violates Section 301(a) of the FD&C Act, while receiving them in interstate commerce violates Section 301(c).

Theme 2: Traditional vs. Outsourcing Compounding Frameworks (Sections 503A and 503B)

To qualify for exemptions from the FDA’s new drug approval requirements (Section 505), CGMP requirements (Section 501(a)(2)(B)), and labeling with adequate directions for use (Section 502(f)(1)), compounded drugs must adhere to the conditions of Section 503A or Section 503B of the FD&C Act.

• Section 503A (Traditional Pharmacies): Prohibits pharmacies from regularly compounding, or compounding in inordinate amounts, drug products that are essentially copies of commercially available drug products. A compounded drug is not considered a copy under Section 503A if a change produces a “significant difference” for the patient, as determined by the prescribing practitioner.
• Section 503B (Outsourcing Facilities): Permits compounding from bulk drug substances only if the substance appears on the FDA’s 503B bulks list, or if the drug appears on the FDA’s drug shortage list under Section 506E at the time of compounding, distribution, and dispensing.

The FDA’s Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A describes the conditions under which bulk drug substances may be used while the 503A bulks list is being developed; its current version was finalized in January 2025. If a compounder fails to meet these statutory conditions, its products are unapproved new drugs and misbranded drugs, making their distribution a federal violation.

Theme 3: The End of Enforcement Discretion and Its Impact

During the GLP-1 supply shortages, the FDA exercised enforcement discretion for compounders making semaglutide and tirzepatide injection products that were essentially copies of commercially available drugs. After the shortages were declared resolved, the FDA announced when that discretion would end:

• Tirzepatide: The shortage was declared resolved on December 19, 2024. Enforcement discretion ended on March 5, 2025 for state-licensed pharmacies (503A) and on March 19, 2025 for outsourcing facilities (503B).
• Semaglutide: The shortage was declared resolved on February 21, 2025. Enforcement discretion ended on April 24, 2025 for state-licensed pharmacies (503A) and on May 22, 2025 for outsourcing facilities (503B).

Consequently, compounding these drugs as essentially copies of commercially available products is no longer covered by enforcement discretion.

Additionally, the FDA has warned against unauthorized salt forms of semaglutide, such as semaglutide sodium and semaglutide acetate. These salt forms are different active ingredients from the one used in FDA-approved drugs (Ozempic, Wegovy, Rybelsus) and have not been shown to be safe or effective. They do not qualify for the compounding exemptions under Section 503A or 503B, and FDA says they should not be used to compound.

Theme 4: Next-Generation Peptides and Unapproved APIs

The FDA has expanded its enforcement to the compounding, marketing, and distribution of next-generation and multi-receptor agonist peptides. This includes retatrutide (a triple GLP-1/GIP/glucagon receptor agonist, often labeled as “GLP-3 RT”) and cagrilintide (an amylin analog).

These peptides are ineligible for the compounding exemptions under Sections 503A and 503B because they fail the statutory conditions:

1. They are not the subject of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph.
2. They are not components of any FDA-approved human drug.
3. They do not appear on the FDA’s 503A or 503B bulk drug substances lists.
4. They are not on the FDA’s drug shortage list.

On September 9, 2025, the FDA issued warning letters to online sellers including GenLabMeds, GLP-1 Solution, Trust Labs, MedClub and Amazing Meds for marketing retatrutide. The agency has also acted against bulk ingredient suppliers: its December 8, 2025 warning letter to Darmerica, LLC names retatrutide and cagrilintide acetate as APIs that are not eligible for compounding under Section 503A.

To get around these rules, many sellers label products “research use only” or “not for human consumption.” The FDA has made clear, for example in its March 31, 2026 warning letter to Gram Peptides, that such labels do not change a product’s status as a drug when there is evidence it is intended for human use, such as selling it with bacteriostatic water for reconstitution or making therapeutic claims about weight reduction and blood glucose.

Theme 5: Good Laboratory Practice (GLP) Nonclinical Violations

A distinction must be made between enforcement actions targeting GLP-1 receptor agonist drugs and those targeting nonclinical laboratories for Good Laboratory Practice (GLP) violations. While they share an acronym, GLP laboratory compliance falls under 21 CFR Part 58 and governs the quality and integrity of nonclinical laboratory studies that support applications for FDA-regulated products.

The FDA’s Center for Devices and Radiological Health (CDRH) has issued warning letters to several international testing laboratories for serious GLP violations, including:

• Mid-Link Testing Company (China): September 10, 2024.
• Sanitation & Environmental Technology Institute, dba SDWH (China): September 10, 2024. The FDA announced both 2024 letters together.
• Jiangsu Kerbio Medical Technology Group (China): July 11, 2025.
• Palamur Biosciences (India): December 11, 2025.

These actions underscore the FDA’s broader focus on data integrity across product development and laboratory testing, in parallel with its enforcement in the GLP-1 drug market.

4. Data Analysis & Results

To show the breadth of the FDA’s enforcement, this section summarizes the warning letters, statutory provisions, and regulatory milestones reviewed for this report. Each firm name links to its warning letter on the FDA’s website.

Table 1: Key FDA Warning Letters and Targeted Entities (2024–2026)

Table 2: Core Statutory Violations under the FD&C Act

Table 3: Compounding Eligibility and Regulatory Status of Key Peptides

Shortage status is from the FDA Drug Shortages database and the FDA’s compounding policy statement.

Table 4: Key Enforcement Discretion and Shortage Milestones

Qualitative Analysis and Thematic Coding

A qualitative analysis of the warning letters reveals a progression in the FDA’s enforcement strategy. In 2024 and 2025, many letters went to online peptide sellers marketing “research use only” products directly to consumers.

By 2026, the FDA had shifted its focus to the institutional pillars of the parallel market:

1. Telehealth Platforms: Targeted for marketing and advertising violations, specifically false equivalence claims and misleading branding.
2. High-Volume Compounding Pharmacies: Targeted for failing to meet the conditions of Section 503A, specifically the prohibition on compounding essentially copies of commercially available drugs.

This shift indicates that the FDA is no longer only policing the fringes of the market but is addressing the commercial infrastructure that supports the unauthorized GLP-1 trade.

5. Discussion

The findings of this report highlight a turning point in the GLP-1 market. The period of regulatory flexibility driven by drug shortages has ended.

The Empower Pharmacy Case Study (September 18, 2026)

The warning letter issued to Empower Pharmacy (Empower Clinic Services, LLC) on September 18, 2026 is a landmark compliance case study. Following an FDA inspection from November 3 through November 14, 2025, the FDA determined that the pharmacy was compounding drug products that were essentially copies of commercially available, FDA-approved drugs regularly or in inordinate amounts, and so did not meet the conditions of Section 503A of the FD&C Act.

The products cited include:

• Tirzepatide/Niacinamide (4 mL) (17/2 mg/mL)
• Tirzepatide/Niacinamide (2.5 mL) (8/2 mg/mL)
• Semaglutide/Cyanocobalamin (1 mL) (5/0.5 mg/mL)

The FDA stated that the volume of production suggested that the differences between these products and the approved drugs were pretextual rather than clinically significant, and it questioned templated prescriber statements of a “significant difference.” Under Section 503A, a compounded drug is exempt from the “essentially a copy” restriction only if a change produces a significant difference for the individual patient, as determined by the prescriber. The letter also cited insanitary conditions and CGMP violations.

Practical Applications for Industry Stakeholders

The FDA’s stance has immediate practical implications for market participants:

1. For Telehealth Providers: Platforms must audit their marketing materials, websites, and social media advertisements. Any claims implying that compounded semaglutide or tirzepatide is “generic,” “identical,” or “FDA-approved” must be removed. Labels must reflect the actual compounding pharmacy and avoid branding that obscures the source of the medication.
2. For Compounding Pharmacies: Pharmacies must limit their compounding of semaglutide and tirzepatide to genuine, patient-specific clinical needs documented by the prescriber. Adding vitamins (like B12 or niacinamide) to create a standardized product line risks being treated by the FDA as a pretextual difference.
3. For API Distributors: Suppliers must stop distributing unapproved next-generation peptides like retatrutide and cagrilintide to compounding pharmacies, as these substances are not eligible for compounding.

Limitations and Alternative Explanations

While the FDA’s enforcement actions are designed to protect public health from unapproved and potentially unsafe medications, some industry advocates argue that strict rules may restrict patient access. Compounding pharmacies often argue that minor formulation changes (such as adding cyanocobalamin to reduce nausea) provide genuine clinical benefits. However, the FDA’s recent warning letters make clear that the agency will prioritize the statutory conditions and standardized safety evaluation over market-driven access arguments.

6. Conclusions

Direct Answers to Research Questions

1. Primary Violations: The FDA’s warning letters primarily cite Sections 502(a) and 502(bb) (misbranding due to false or misleading claims), Section 505(a) (unapproved new drugs), Section 502(f)(1) (lack of adequate directions for use), and Section 301 (prohibited acts in interstate commerce).
2. “Essentially a Copy” Restriction: Under Section 503A, a pharmacy may not regularly or in inordinate amounts compound copies of commercially available drugs, unless a change produces a significant difference for the patient, as determined by the prescriber. Under Section 503B, a drug is essentially a copy of an approved drug if it has the same active ingredient, route of administration, and strength (with exceptions). In the Empower letter, the FDA treated high-volume additive combinations as pretextual differences.
3. Next-Generation Peptides: Peptides like retatrutide and cagrilintide are ineligible for compounding under Sections 503A and 503B because they lack USP/NF monographs, are not components of any FDA-approved human drug, and are not on the bulks or shortage lists.
4. End of Enforcement Discretion: Enforcement discretion ended in 2025 (tirzepatide: March 5 for 503A and March 19 for 503B; semaglutide: April 24 for 503A and May 22 for 503B), so compounding these drugs as copies of commercially available products is no longer covered, regardless of local demand.

Recommendations

• To Telehealth Platforms: Shift marketing away from compounded GLP-1s toward FDA-approved products, or ensure that any compounded offerings meet the patient-specific requirements of Section 503A.
• To Regulators: Continue to provide clear, timely updates on the FDA Drug Shortage List so compounders know when a shortage has been resolved.
• To Compounding Pharmacies: Run compliance audits to ensure that bulk drug substances are used only when they meet the Section 503A or 503B conditions.

Future Research Directions

Future research should monitor clinical outcomes and adverse event reports for compounded GLP-1 formulations compared with FDA-approved drugs. Longitudinal studies are also needed to assess the economic impact of the FDA’s 2025–2026 enforcement on the telehealth industry and on patient adherence.